EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Multidimensional Healthcare Access Barriers to Prostate‐Specific Antigen Testing: A Nation‐Wide Panel Study in the United States From 2006 to 2020

Hari S Iyer iD, Kevin H Kensler iD, Charlotte Roscoe, Chidinma Opara, Mingchao He, Evan Kovac, Isla P Garraway iD, Quoc Dien-Trinh iD, Timothy R Rebbeck iD

Cancer Medicine · 2024

DOI: 10.1002/cam4.70358 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Hari S Iyer und 8 weiteren Autor:innen. Beteiligte Einrichtung: Section of Cancer Epidemiology and Health Outcomes, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA. Hauptthemen laut MEDLINE: Prostate-Specific Antigen, Health Services Accessibility, Prostatic Neoplasms, Early Detection of Cancer. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: U.S. Department of Defense, Prostate Cancer Research UK, NIEHS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Rising metastatic prostate cancer incidence has renewed debate regarding benefits of prostate‐specific antigen (PSA) screening. Identifying barriers to accessing screening for individuals at high risk of lethal prostate cancer may slow this rise. We examined associations of access barriers with receipt of PSA testing, stratified by sociodemographic factors.

Methods

We pooled data from male respondents to Behavior Risk Factor Surveillance Systems (BRFSS) surveys from 2006 to 2020. Questions related to affordability (insurance, cost of visits) and accommodation (regular primary care provider (PCP), physician recommending a PSA test) were considered as individual‐level barriers. For availability, we linked provider density from the 2012 Area Health Resource File and estimated driving times to closest health facility within Micropolitan and Metropolitan Statistical Area (MMSA) using Google Earth Engine. These measures were used to compute a spatial accessibility index. We fit survey‐weighted, covariate‐adjusted logistic regression models to estimate associations of barriers with receipt of PSA within the past 2 years and examined effect modification by sociodemographic factors.

Results

There were 185,643 participants, of whom 73% were White, 11% were Black, 4% were Asian, and 11% were Hispanic. Physician recommendation was the strongest predictor of having a PSA test (aOR: 14.5, 95% CI: 13.6, 15.6). Not having a regular PCP (aOR: 0.29, 95% CI: 0.27, 0.31), insurance (aOR: 0.64, 95% CI: 0.58, 0.71), and prohibitive cost of care (aOR: 0.82, 95% CI: 0.75, 0.90) were associated with lower PSA testing. Access barriers were stronger predictors of PSA testing for Asian and White participants compared to other groups ( P het < 0.004 for insurance and regular PCP) and for those with college education compared to those without ( P het < 0.05 for insurance, perceived unaffordability).

Discussion

Physician recommendation was the strongest predictor of receipt of PSA testing, regardless of sociodemographic grouping. Future studies should consider access barriers jointly and across sociodemographic strata.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostate-Specific AntigenHealth Services AccessibilityProstatic NeoplasmsEarly Detection of CancerHumansMaleUnited StatesMiddle AgedAgedAdultBehavioral Risk Factor Surveillance System

Stichwörter der Autor:innen

accessibility of health servicescancer screeningprostate‐specific antigenprostatic neoplasmsracial groups

Substanzen

Prostate-Specific Antigen

Autor:innen und Institutionen

  • Section of Cancer Epidemiology and Health Outcomes, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA.
  • Department of Population Health Sciences, Weill Cornell Medical Center, New York, New York, USA.
  • Division of Population Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Department of Environmental Health, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.
  • Rutgers Cancer Institute of New Jersey, Newark, New Jersey, USA.
  • Department of Surgical and Perioperative Care, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California, USA.

ORCID-Profile: Hari S Iyer, Kevin H Kensler, Isla P Garraway, Quoc Dien-Trinh, Timothy R Rebbeck

Förderung

  • U.S. Department of Defense
  • Prostate Cancer Research UK
  • NIEHS NIH HHS
  • NIH HHS
  • NCI NIH HHS
  • Prostate Cancer Foundation
  • Jean Perkins Foundation
  • National Institutes of Health

Zitieren

APA

Iyer, H. S., Kensler, K. H., Roscoe, C., Opara, C., He, M., Kovac, E., Garraway, I. P., Dien-Trinh, Q., & Rebbeck, T. R. (2024). Multidimensional Healthcare Access Barriers to Prostate‐Specific Antigen Testing: A Nation‐Wide Panel Study in the United States From 2006 to 2020. Cancer Medicine. https://doi.org/10.1002/cam4.70358

Vancouver

Iyer HS, Kensler KH, Roscoe C, Opara C, He M, Kovac E, et al. Multidimensional Healthcare Access Barriers to Prostate‐Specific Antigen Testing: A Nation‐Wide Panel Study in the United States From 2006 to 2020. Cancer Medicine. 2024. doi:10.1002/cam4.70358

BibTeX
@article{Iyer2024,
  author = {Iyer, Hari S and Kensler, Kevin H and Roscoe, Charlotte and Opara, Chidinma and He, Mingchao and Kovac, Evan and Garraway, Isla P and Dien-Trinh, Quoc and Rebbeck, Timothy R},
  title = {Multidimensional Healthcare Access Barriers to Prostate‐Specific Antigen Testing: A Nation‐Wide Panel Study in the United States From 2006 to 2020},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.70358}
}
Kostenlos starten →